<DOC>
	<DOCNO>NCT01814488</DOCNO>
	<brief_summary>The experimental treatment consist application therapeutic strategy allogeneic transplantation potential curative procedure population patient chemoresistant acute leukemia . Therapeutic intervention , namely condition regimen well GVHD prophylaxis , base regimen currently standard use context allogeneic transplantation .</brief_summary>
	<brief_title>A Phase II Study Allogeneic Stem Cell Transplantation Patients With Active Acute Leukemia</brief_title>
	<detailed_description>The experimental treatment consist application therapeutic strategy allogeneic transplantation use either Marrow Unrelated Donor ( MUD ) Cord Blood ( CB ) unit family Haploidentical ( Haplo ) donor potential curative procedure population patient chemoresistant acute leukemias increase overall survival patient . Therapeutic intervention , namely condition regimen well GVHD prophylaxis , base regimen currently standard use context allogeneic transplantation . The Data Safety Monitoring Board ( DSMB ) collaboration Steering Committee ( SC ) make periodic monitoring ensure safety patient enrol study . In particular , DSMB check periodic safety report serious adverse event , primary secondary graft failure treat related mortality ( TRM ) data generate Data Management Center . A safety report generate every 30 enrol patient complete 100 day follow-up . The population analysis trial Intention Treat ( ITT ) population . All patient enrol study include ITT analysis . This study explore feasibility , safety efficacy allogeneic stem cell transplantation unrelated , cord-blood haploidentical donor patient active leukemia . Due lack detailed information literature absence alternative curative option patient population , criterion sample size assessment refer formal statistical power calculation . Therefore , GITMO promote enrollment patient active leukemia eligible allogeneic SCT Italian centre aim collect outcome variable ITT wide representative cohort specific patient population . The choice 80 patient transplant base feasibility reason expect patient population characteristic refer main Italian Transplant Centres two year . GITMO survey data transplant activity point estimate accrual 40 patient per year 24 month enrolment period . Criteria define sample size follow statistical power estimate order demonstrate difference alternative donor option .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Diagnosis Primary induction Failure chemoresistant relapse Acute Myeloid Leukemia ( AML ) Acute Lymphoblastic Leukemia ( ALL ) patient Activation alternative donor search Italian Bone Marrow Donor Registry ( IBMDR ) Age &gt; =18 &lt; =70 Unavailability HLAmatched relate donor ( MRD ) Performance status : ECOG &lt; =3 Written sign inform consent Life expectancy severely limited concomitant illness . Previous allogeneic transplant ( autologous transplant accept ) Positive pregnancy test Any active , uncontrolled infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Active acute leukemia</keyword>
	<keyword>PIF</keyword>
	<keyword>Allogeneic transplant</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Marrow Unrelated Donor</keyword>
	<keyword>Cord Blood</keyword>
	<keyword>Family Haploidentical donor</keyword>
</DOC>